Fiche centre
West Tennessee Research Institute
Jackson — United States
Essais liés7clinical trials
VilleJacksonlocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05624749
Essais cliniques associés
7| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Nerandomilast | Myopathies | Phase 3 | NCT07789015 | VERANDA™-IIM — A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies | NOT_YET_RECRUITING |
| Ianalumab | Lupus | Phase 3 | NCT05624749 | Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) | ACTIVE_NOT_RECRUITING |
| Nipocalimab | Lupus | Phase 3 | NCT07438496 | GARDENIA-SLE — A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus | RECRUITING |
| LUPKYNIS | Lupus | Phase 4 | NCT07611214 | PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis | RECRUITING |
| BI 3000202 | Lupus | Phase 2 | NCT07409181 | A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE) | RECRUITING |
| Litifilimab | Lupus | Phase 3 | NCT05352919 | EMERALD — An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus | ENROLLING_BY_INVITATION |
| Ianalumab | Lupus | Phase 3 | NCT06133972 | Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). | RECRUITING |